We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Read MoreHide Full Article
Key Takeaways
CAPR's BLA for deramiocel in DMD cardiomyopathy received an FDA complete response letter.
The FDA cited a lack of substantial evidence and unresolved CMC issues in the BLA.
CAPR plans talks with the FDA to clarify issues and chart a regulatory path for deramiocel.
Shares of Capricor Therapeutics (CAPR - Free Report) tanked 33% on Friday after it announced that the FDA issued a complete response letter (“CRL”) to the biologics license application (“BLA”) seeking approval for cell therapy deramiocel, to treat cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”).
DMD is a serious genetic disorder showing progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years.
Per the CRL, the FDA informed the company that it had concluded review of the BLA but could not approve the application in the current form. The regulatory body specifically noted that the application failed to meet the statutory requirement for substantial evidence of effectiveness and highlighted the need for additional clinical data.
The CRL also highlighted certain unresolved issues within the Chemistry, Manufacturing and Controls (“CMC”) section of the application. Management believes that most of these concerns have already been addressed in its prior communications with the FDA. However, the FDA did not review these materials, as they were submitted too close to the issuance of the CRL.
Year to date, shares of Capricor have plunged 44.7% compared with the industry’s decline of 0.9%.
Image Source: Zacks Investment Research
CRL to CAPR's BLA Comes as a Major Surprise
The investor community seemed surprised by the CRL, especially after the FDA accepted and granted a priority review to the BLA for deramiocel in March. A decision was due on Aug. 31, 2025. More so, the FDA also did not identify any review issues with the BLA.
In a regulatory update provided last month, the company also confirmed that the FDA indicated an Advisory Committee meeting would not be required for the application.
The BLA was based on data from its phase II HOPE-2 and an open-label extension study compared with natural history data.
A potential approval could have made deramiocel the first therapy to treat DMD cardiomyopathy. However, the latest CRL is likely to delay the approval for deramiocel, which could have given Capricor its first approved product.
The company plans to hold further discussions with the FDA to determine the next steps of development for deramiocel.
In the past 60 days, Arvinas’ 2025 loss per share estimates have improved from $1.60 to $1.51. Loss per share estimates for 2026 have narrowed from $3.28 to $2.98 during the same period. ARVN stock has plunged 59.3% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.
In the past 60 days, estimates for Alkermes’ earnings per share have increased from $1.74 to $1.79 for 2025. During the same time, earnings per share estimates for 2026 have risen from $1.79 to $1.91. Year to date, shares of ALKS have gained 5.3%.
Alkermes’ earnings beat estimates in one of the trailing four quarters, while missing the same on the remaining three occasions, the negative average surprise being 8.24%.
In the past 60 days, BioXcel Therapeutics’ 2025 loss per share estimates have improved from $16.44 to $8.60. Loss per share estimates for 2026 have narrowed from $23.76 to $7.02 during the same period. BTAI stock has declined 67.1% year to date.
BioXcel Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 42.84%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Key Takeaways
Shares of Capricor Therapeutics (CAPR - Free Report) tanked 33% on Friday after it announced that the FDA issued a complete response letter (“CRL”) to the biologics license application (“BLA”) seeking approval for cell therapy deramiocel, to treat cardiomyopathy associated with Duchenne muscular dystrophy (“DMD”).
DMD is a serious genetic disorder showing progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years.
Per the CRL, the FDA informed the company that it had concluded review of the BLA but could not approve the application in the current form. The regulatory body specifically noted that the application failed to meet the statutory requirement for substantial evidence of effectiveness and highlighted the need for additional clinical data.
The CRL also highlighted certain unresolved issues within the Chemistry, Manufacturing and Controls (“CMC”) section of the application. Management believes that most of these concerns have already been addressed in its prior communications with the FDA. However, the FDA did not review these materials, as they were submitted too close to the issuance of the CRL.
Year to date, shares of Capricor have plunged 44.7% compared with the industry’s decline of 0.9%.
Image Source: Zacks Investment Research
CRL to CAPR's BLA Comes as a Major Surprise
The investor community seemed surprised by the CRL, especially after the FDA accepted and granted a priority review to the BLA for deramiocel in March. A decision was due on Aug. 31, 2025. More so, the FDA also did not identify any review issues with the BLA.
In a regulatory update provided last month, the company also confirmed that the FDA indicated an Advisory Committee meeting would not be required for the application.
The BLA was based on data from its phase II HOPE-2 and an open-label extension study compared with natural history data.
A potential approval could have made deramiocel the first therapy to treat DMD cardiomyopathy. However, the latest CRL is likely to delay the approval for deramiocel, which could have given Capricor its first approved product.
The company plans to hold further discussions with the FDA to determine the next steps of development for deramiocel.
Capricor Therapeutics, Inc. Price
Capricor Therapeutics, Inc. price | Capricor Therapeutics, Inc. Quote
CAPR's Zacks Rank & Stocks to Consider
Capricor currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the biotech sector are Arvinas (ARVN - Free Report) , Alkermes (ALKS - Free Report) and BioXcel Therapeutics (BTAI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, Arvinas’ 2025 loss per share estimates have improved from $1.60 to $1.51. Loss per share estimates for 2026 have narrowed from $3.28 to $2.98 during the same period. ARVN stock has plunged 59.3% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.
In the past 60 days, estimates for Alkermes’ earnings per share have increased from $1.74 to $1.79 for 2025. During the same time, earnings per share estimates for 2026 have risen from $1.79 to $1.91. Year to date, shares of ALKS have gained 5.3%.
Alkermes’ earnings beat estimates in one of the trailing four quarters, while missing the same on the remaining three occasions, the negative average surprise being 8.24%.
In the past 60 days, BioXcel Therapeutics’ 2025 loss per share estimates have improved from $16.44 to $8.60. Loss per share estimates for 2026 have narrowed from $23.76 to $7.02 during the same period. BTAI stock has declined 67.1% year to date.
BioXcel Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 42.84%.